In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
Fluciclovine PET/CT plus conventional imaging vs conventional imaging alone to guide radiation therapy for men with recurrent PCa following radical prostatectomy results in improved failure-free survival, according to the first randomized trial comparing the 2 approaches.
Pretreatment counts of 5 CTCs per 7.5 mL of blood or higher correlated with shorter survival compared with lower counts among men with metastatic castration-resistant prostate cancer treated with radium-223, a study found.
Among men on active surveillance or watchful waiting for low- and intermediate-risk prostate cancer (PCa), Blacks had a shorter median time from PCa diagnosis to definitive therapy compared with Whites.